Openbookopenbook
Equity
Oxford Nanopore Technologies Limited(ONTTF)
USD --+0.00%
Reward48Moderate
Risk54Moderate
📊75%Data
Thin -70% profit margin · Revenue growing 26% YoY
ONTTF
+0.0 · +0.00%
USD · PINK
Oxford Nanopore Technologies Limited | Healthcare
Capital Destroyer
Market Cap:1.79Bn
ℹ️
Reward Rating
48
Moderate
Bottom 25% (model universe)
75% data coverage
ℹ️
Risk Rating
54
Moderate
Risk Assessment
ℹ️

Educational tool only – Scores are based on historical data and financial metrics for informational purposes. This is not financial advice or a recommendation to buy or sell any security. Always conduct your own research or consult a qualified financial adviser.

ℹ️ Educational tool only · More
Limited data coverage
We don't have enough public data on ONTTF to score it reliably yet — Reward, Risk, Forecasts and Dividends tabs aren't available for this stock. The price chart and basic profile are still shown.
OTC / ADR stock — scores and fundamentals use data tagged in USD by our provider. The issuer may report in a different home currency (e.g. JPY), so treat figures as directional rather than precise.
Not available for limited-coverage stocks
The overview tab requires fundamentals and price history we don't have for this stock. The price chart is the most reliable view we have — try the Chart tab.

Market Performance

Stock returned +10.0% over the past year, broadly in line with market conditions.

What is Oxford Nanopore Technologies Limited?

Oxford Nanopore Technologies plc engages in the research, development, manufacture, and commercialization of a novel generation of deoxyribonucleic acid (DNA) or ribonucleic acid (RNA) sequencing technology that allows the real-time analysis of DNA or RNA.

ONTTF · Verdict

Moderate reward · elevated risk

ONTTF has limited near-term tailwinds — cash flow and profitability weigh on the model output.

Based on 88% data coverage

ONTTF · Verdict

What’s working & what to watch

Watchouts 2

  • Cash flow20/100

    -87% free-cash-flow margin

  • Profitability28/100

    -80% net margin · -26% ROE

Model-based scoring. For information only — not financial advice.

What is Oxford Nanopore Technologies Limited?

Oxford Nanopore Technologies plc engages in the research, development, manufacture, and commercialization of a novel generation of deoxyribonucleic acid (DNA) or ribonucleic acid (RNA) sequencing technology that allows the real-time analysis of DNA or RNA. It offers MinION Mk 1D, a portable device for DNA and RNA; GridION and GridION Q, a compact bench top device, which delivers a version of hardware, software, and chemistry. The company is listed on the PINK in USA, operating in the Healthcare sector, with a market capitalisation of 1.79B.

Financial Highlights

Investment Breakdown

📈 Growth
Revenue and earnings growing steadily, indicating improving operating performance.
💰 Profitability
Thin or inconsistent margins weigh on earnings quality.
⚠️ Risk
Risk profile appears balanced versus broad market conditions.
💸 Valuation
Valuation is less clear with a negative earnings base.

OpenBook Logo Analysis

Reward: Moderate (48)

The scoring profile indicates limited reward potential at this time, with growth and valuation offering the most support. Risk indicators are elevated — volatility and macro sensitivity warrant consideration.

For informational purposes only. Not financial advice.

Company Information
SectorHealthcare
Market Cap1.79B
P/E RatioN/A
Dividend YieldN/A
52 Week High3.34
52 Week Low1.07
Last AnnualDecember
IPO DateN/A
IncorporatedUSA
Shares Outstanding967M
No. of Employees1,325
IndustryBiotechnology
ExchangePINK
Beta0.886
CurrencyUSD · Reports in GBP
Websitenanoporetech.com
openbook

Stock research for everyday UK investors. Make smarter decisions, faster.

Questions? Email us at contact@openbookanalytics.com

© 2026 Openbook Analytics Ltd · Company No. SC843579 · Registered in Scotland

256-bit encryption GDPR compliant UK data centres

Openbook Analytics Ltd (Company No. SC843579) is registered in Scotland. Registered office: Strathclyde Inspire Hub, University of Strathclyde, Graham Hills Building (Level 6), 50 Richmond Street, Glasgow, G1 1XP. Openbook Analytics is not authorised or regulated by the Financial Conduct Authority (FCA). The content on this platform is provided for general informational and educational purposes only and does not constitute financial advice, investment advice, trading advice, or any other form of advice. You should not treat any content on this platform as a recommendation to buy, sell, or hold any financial instrument. Past performance is not a reliable indicator of future results. The value of investments and the income from them can go down as well as up, and you may get back less than you invest. User-generated content, including community posts and commentary, reflects the personal opinions of individual users, is not verified for accuracy, and does not represent the views of Openbook Analytics Ltd. You should always conduct your own research or consult a qualified, FCA-regulated financial adviser before making investment decisions. Data displayed on this platform may be delayed or inaccurate and is provided "as is" without warranty. Openbook Analytics Ltd accepts no liability for any loss arising from reliance on the information provided.